A pilot study of Imaging in Stereotactic Ablative Frameless Radiosurgery for Oligometastatic Neoplasia to the lung.

Peter MacCallum Cancer Centre0 个研究点目标入组 10 人开始时间: 2013年7月4日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•One or two metastases within the lung parenchyma.
•Patients with primary cancers of epithelial, sarcomatoid or germ cell histologies who are treated with curative intent.
•Aged 18 years or older.
•ECOG performance of 0-2 inclusive.
•The tumour must have a peripheral location, defined as at least 1cm beyond the mediastinum and beyond the bifurcation of the lobar bronchi.
•Maximal tumour diameter < 5cm.
•No known extrathoracic disease prior to enrollment. Primary is controlled.
•Patient has provided written informed consent for participation in this trial prior to any protocol specific procedures.
•Patient must be medically inoperable, have technically high risk disease for surgery or refuse surgery.

•Previous high-dose thoracic radiotherapy.
•Cytotoxic chemotherapy within 3 weeks of commencement of treatment, or concurrently with treatment. Hormonal manipulation agents are not excluded (e.g. aromatase inhibitors, selective oestrogen receptor modulators, and gonadotrophin releasing hormone receptor modulators).
•Any patient who is currently pregnant or breastfeeding.

发起方

Peter MacCallum Cancer Centre